Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

The Effect of Walking in Kidney Transplant Patients

6. august 2021 opdateret af: FATMA DEMIR KORKMAZ, Ege University

The Effect of Pedometer Assisted Walking on Physical Activity Level and Metabolic Parameters in Patients With Renal Transplantation

Cardiovascular diseases are among the most common causes of death in kidney transplant patients. Physical activity is of great importance in preventing cardiovascular diseases after transplantation. Although regular physical activity is recommended in international guidelines to prevent post-transplant mortality and morbidity in kidney transplant patients, studies have shown that patients do not follow regular physical activity instructions.The aim of our project is to examine the effect of pedometer-assisted physical activity on metabolic parameters after kidney transplantation.

Studieoversigt

Status

Rekruttering

Intervention / Behandling

Detaljeret beskrivelse

Patients with kidney transplant surgery will be randomized to the intervention (n: 34) and control groups (n: 34), respectively, according to the transplant surgery date. Intervention and Control groups will be given the same training on the importance of physical activity during discharge training. The pedometer will be given to the intervention group to evaluate the activity level, and it will be said that their goal is to take 2000 steps in 20 minutes a day after discharge. Patients will be asked to carry the pedometer during physical activity, and to write down the number of steps they take in 20 minutes on the form given to them for 90 days. Patients in the control group will only be advised to do physical activity every day and will be asked to record the minutes of physical activity they do for 90 days. Metabolic parameters of the patients in the intervention and control groups will be examined at the end of the 4th and 12th months. These parameters are blood pressure, body mass index, complete blood count (hemoglobin, leukocyte, thrombocyte), blood glucose, sodium, potassium, calcium, liver enzymes, serum creatinine, total and indirect bilirubin, albumin and total cholesterol levels.

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

68

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria: • Over the age of 18 and under the age of 65,

  • Kidney transplantation at the center where the study was conducted between the research dates,
  • There is no activity restriction recommendation by the physician,
  • Patients who agree to participate in the study.

Exclusion Criteria:

  • Multiple organ transplantation at the same time,
  • Death or graft loss/rejection in the hospital before discharge,
  • Patients with physical activity restrictions by the physician,
  • Patients who are re-hospitalized within the first 3 months after discharge

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Using a pedometer
The pedometer will be given to the intervention group to evaluate the activity level and to encourage a walk , it will be said that their goal is to take 2000 steps in 20 minutes a day after discharge. Patients will be asked to carry the pedometer during physical activity, and to write down the number of steps they take in 20 minutes on the form given to them for 90 days.
2000 steps per day in 20 minutes for 90 days, guided by a pedometer after a kidney transplantation
Ingen indgriben: Not using a pedometer
The control group will not be given a pedometer.Patients in the control group will only be instructed to do physical activity every day and will be asked to record the minutes of physical activity they do for 90 days.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Blood Pressure
Tidsramme: Change from Baseline Blood Pressure at 4 months after discharge
mmHg
Change from Baseline Blood Pressure at 4 months after discharge
Blood Pressure
Tidsramme: Change from Baseline Blood Pressure at 12 months after discharge
mmHg
Change from Baseline Blood Pressure at 12 months after discharge
Body Mass Index (BMI)
Tidsramme: Change from Baseline BMI at 4 months after discharge
BMI is weight in kilograms divided by height in meters squared. Formula: weight (kg) / [height (m)]2
Change from Baseline BMI at 4 months after discharge
Body Mass Index (BMI)
Tidsramme: Change from Baseline BMI at 12 months after discharge
BMI is weight in kilograms divided by height in meters squared. Formula: weight (kg) / [height (m)]2
Change from Baseline BMI at 12 months after discharge
Hemoglobin
Tidsramme: Change from Baseline Hemoglobin at 4 months after discharge
g/dL
Change from Baseline Hemoglobin at 4 months after discharge
Hemoglobin
Tidsramme: Change from Baseline Hemoglobin at 12 months after discharge
g/dL
Change from Baseline Hemoglobin at 12 months after discharge
Leukocyte
Tidsramme: Change from Baseline Leukocyte at 4 months after discharge
10^3/µL
Change from Baseline Leukocyte at 4 months after discharge
Leukocyte
Tidsramme: Change from Baseline Leukocyte at 12 months after discharge
10^3/µL
Change from Baseline Leukocyte at 12 months after discharge
Thrombocyte
Tidsramme: Change from Baseline Thrombocyte at 4 months after discharge
10^3/µL
Change from Baseline Thrombocyte at 4 months after discharge
Thrombocyte
Tidsramme: Change from Baseline Thrombocyte at 12 months after discharge
10^3/µL
Change from Baseline Thrombocyte at 12 months after discharge
Blood Glucose
Tidsramme: Change from Baseline Blood Glucose at 4 months after discharge
mg/dL
Change from Baseline Blood Glucose at 4 months after discharge
Blood Glucose
Tidsramme: Change from Baseline Blood Glucose at 12 months after discharge
mg/dL
Change from Baseline Blood Glucose at 12 months after discharge
Sodium
Tidsramme: Change from Baseline Sodium at 4 months after discharge
mEq/L
Change from Baseline Sodium at 4 months after discharge
Sodium
Tidsramme: Change from Baseline Sodium at 12 months after discharge
mEq/L
Change from Baseline Sodium at 12 months after discharge
Potassium
Tidsramme: Change from Baseline Sodium at 4 months after discharge
mEq/L
Change from Baseline Sodium at 4 months after discharge
Potassium
Tidsramme: Change from Baseline Sodium at 12 months after discharge
mEq/L
Change from Baseline Sodium at 12 months after discharge
Calcium
Tidsramme: Change from Baseline Sodium at 4 months after discharge
mEq/L
Change from Baseline Sodium at 4 months after discharge
Calcium
Tidsramme: Change from Baseline Sodium at 12 months after discharge
mEq/L
Change from Baseline Sodium at 12 months after discharge
Serum Creatinine
Tidsramme: Change from Baseline Sodium at 4 months after discharge
mg/dL
Change from Baseline Sodium at 4 months after discharge
Serum Creatinine
Tidsramme: Change from Baseline Sodium at 12 months after discharge
mg/dL
Change from Baseline Sodium at 12 months after discharge
Total Bilirubin
Tidsramme: Change from Baseline Sodium at 4 months after discharge
mg/dL
Change from Baseline Sodium at 4 months after discharge
Total Bilirubin
Tidsramme: Change from Baseline Sodium at 12 months after discharge
mg/dL
Change from Baseline Sodium at 12 months after discharge
Indirect Bilirubin
Tidsramme: Change from Baseline Sodium at 4 months after discharge
mg/dL
Change from Baseline Sodium at 4 months after discharge
Indirect Bilirubin
Tidsramme: Change from Baseline Sodium at 12 months after discharge
mg/dL
Change from Baseline Sodium at 12 months after discharge
High-density lipoprotein (HDL) cholesterol
Tidsramme: Change from Baseline Sodium at 4 months after discharge
mg/dL
Change from Baseline Sodium at 4 months after discharge
High-density lipoprotein (HDL) cholesterol
Tidsramme: Change from Baseline Sodium at 12 months after discharge
mg/dL
Change from Baseline Sodium at 12 months after discharge
Low-density lipoprotein (LDL) cholesterol
Tidsramme: Change from Baseline Sodium at 4 months after discharge
mg/dL
Change from Baseline Sodium at 4 months after discharge
Low-density lipoprotein (LDL) cholesterol
Tidsramme: Change from Baseline Sodium at 12 months after discharge
mg/dL
Change from Baseline Sodium at 12 months after discharge
Aspartate Aminotransferase
Tidsramme: Change from Baseline Sodium at 4 months after discharge
U/L
Change from Baseline Sodium at 4 months after discharge
Aspartate Aminotransferase
Tidsramme: Change from Baseline Sodium at 12 months after discharge
U/L
Change from Baseline Sodium at 12 months after discharge
Alanine aminotransferase
Tidsramme: Change from Baseline Sodium at 4 months after discharge
U/L
Change from Baseline Sodium at 4 months after discharge
Alanine aminotransferase
Tidsramme: Change from Baseline Sodium at 12 months after discharge
U/L
Change from Baseline Sodium at 12 months after discharge
Alkaline Phosphatase
Tidsramme: Change from Baseline Sodium at 4 months after discharge
U/L
Change from Baseline Sodium at 4 months after discharge
Alkaline Phosphatase
Tidsramme: Change from Baseline Sodium at 12 months after discharge
U/L
Change from Baseline Sodium at 12 months after discharge
Triglyceride
Tidsramme: Change from Baseline Sodium at 4 months after discharge
mg/dL
Change from Baseline Sodium at 4 months after discharge
Triglyceride
Tidsramme: Change from Baseline Sodium at 12 months after discharge
mg/dL
Change from Baseline Sodium at 12 months after discharge
Total Cholesterol
Tidsramme: Change from Baseline Sodium at 4 months after discharge
mg/dL
Change from Baseline Sodium at 4 months after discharge
Total Cholesterol
Tidsramme: Change from Baseline Sodium at 12 months after discharge
mg/dL
Change from Baseline Sodium at 12 months after discharge
Albumin
Tidsramme: Change from Baseline Sodium at 4 months after discharge
g/dL
Change from Baseline Sodium at 4 months after discharge
Albumin
Tidsramme: Change from Baseline Sodium at 12 months after discharge
g/dL
Change from Baseline Sodium at 12 months after discharge
glucose in urine
Tidsramme: Change from Baseline Sodium at 4 months after discharge
mg/dL
Change from Baseline Sodium at 4 months after discharge
glucose in urine
Tidsramme: Change from Baseline Sodium at 12 months after discharge
mg/dL
Change from Baseline Sodium at 12 months after discharge

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Fatma DEMIR KORKMAZ, Professor, Ege University Faculty of Nursing 35000, Izmir, Turkey

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

19. november 2020

Primær færdiggørelse (Forventet)

1. november 2022

Studieafslutning (Forventet)

1. november 2022

Datoer for studieregistrering

Først indsendt

30. marts 2021

Først indsendt, der opfyldte QC-kriterier

6. august 2021

Først opslået (Faktiske)

12. august 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. august 2021

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. august 2021

Sidst verificeret

1. august 2021

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • fatma.demir1

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Hjertesygdom

3
Abonner